Rimonabant,an experimental wonder drug helps you lose weight, quit smoking and it also helps protect your heart. Trials have shown that 33% of people on Rimonabant lost 10% of body weight and kept their weight down for two years - this is a record, no other diet drug has managed to keep a person’s weight down for so long.

The second 33% lost 5% of body weight and kept it down.
It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.

Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two smoking-related therapies: first, to use rimonabant directly to aid in smoking cessation; second, to help prevent weight gain in former smokers. Initial results apparently suggest that rimonabant is effective for both uses.
Tetrahydrocannabinol is known to impair short-term memory.

It was therefore hypothesised that Rimonabant may improve short-term memory. Indeed in animal studies it significantly improved the performance of rats to encode information in the short-term memory.
Acomplia (rimonabant) is also usefull in diabetic blood sugar control.
Based on eight trials now underway, Sanofi Avensis want to submit diet drug Rimonabant Acomplia for worldwide approval as a treatment for type 2 diabetes in 2009, and the European decision to allow inclusion of results from a diabetes studies on the insert suggests more off-label use of the medication for treating diabetes may occur any time soon.
The results come from the so-called SERENADE trial, which compared use of Acomplia to improve blood sugar control (as indicated by the patient’s HbA1c level, a measure of glucose control) in 276 newly diagnosed type 2 diabetic patients who had not yet been treated with any diabetes drug.
In the trial, scientist declared that those on rimonabant treatment saw an average decrease in their HbA1c level of 0.8 compared to 0.3 for those on a placebo, with 51 percent of those on diet drug acomplia rimonabant achieving the treatment target level recommended by the American Diabetes Association.
So based on the facts and the studies we sincearlly recommend the use of Rimonabant,a drug that can help you in so many ways and that can improve the quallity of your life.